List of Besivance drug patents
Besivance is owned by Bausch And Lomb.
Besivance contains Besifloxacin Hydrochloride.
Besivance has a total of 4 drug patents out of which 0 drug patents have expired.
Besivance was authorised for market use on 28 May, 2009.
Besivance is available in suspension/drops;ophthalmic dosage forms.
Besivance can be used as method of treating ocular bacterial infections.
The generics of Besivance are possible to be released after 09 January, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(6 years from now) | |
| US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(7 years from now) | |
| US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(7 years from now) | |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic